List view / Grid view

Retinitis Pigmentosa (RP)

Filter the results

 

news

Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology

18 April 2017 | By Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).

news

NHS England to fund bionic eye surgery

3 January 2017 | By Niamh Louise Marriott, Digital Editor

Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP...

news

MHRA approves bionic vision system clinical trial

31 May 2016 | By Victoria White, Digital Content Producer

Pixium Vision has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK to initiate a clinical trial for patients who have lost sight due to retinitis pigmentosa (RP) with the IRIS II bionic vision system.

article

Examining receptor activation: New technologies reveal how G protein-coupled receptors recognise ligands and talk to intracellular partners

24 June 2010 | By Thomas P. Sakmar, Laboratory of Molecular Biology & Biochemistry, Rockefeller University

Heptahelical G protein-coupled receptors (GPCRs) are arguably the most important single class of pharmaceutical drug targets in the human genome. According to Overington, of the 266 human targets for approved drugs, a remarkable 27 per cent correspond to rhodopsin-like, or Family A, GPCRs. Despite recent dramatic advances in targeting of…